Clearside Biomedical, Inc. CLSDQ

CLSDQ Company Overview

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the development of therapies for serious eye diseases, with a core emphasis on drug delivery to the back of the eye. The company operates within the ophthalmology and biotechnology industries, targeting retinal and choroidal diseases that can lead to vision loss. Its primary value proposition centers on its proprietary suprachoroidal drug delivery platform, which is designed to deliver therapeutics directly to the retina and choroid while potentially reducing off-target exposure.

Clearside was founded in 2011 and became publicly traded in 2016. The company’s strategy historically combined internal drug development with partnerships that leverage its delivery technology. Over time, Clearside shifted from a broad internal pipeline toward a more focused model emphasizing out-licensing and collaboration, particularly after encountering mixed clinical results and capital constraints. In 2023, the company filed for Chapter 11 bankruptcy protection, and its common stock began trading under the ticker CLSDQ, reflecting financial restructuring rather than ongoing commercial operations.